Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - Michiel S. van der Heijden, Thomas Powles, Daniel Castellano, Daniel P. Petrylak, Se Hoon Park, Matthew D. Galsky, Yohann Loriot, Jae-Lyun Lee, Aristotelis Bamias, Osamu Ogawa, Som D. Mukherjee, Marinos Tsiatas, Cristina Suárez, Sophie Wildsmith, Ugo De Giorgi - Dissemin

Language
Login

Published in

Elsevier, The Lancet Oncology, 12(21), p. 1574-1588, 2020

DOI: 10.1016/s1470-2045(20)30541-6

Links

Tools

Export citation

Search in Google Scholar

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Journal article published in 2020 by Michiel S. van der Heijden, Thomas Powles, Daniel Castellano, Daniel P. Petrylak, Se Hoon Park, Matthew D. Galsky, Yohann Loriot, Jae-Lyun Lee, Aristotelis Bamias, Osamu Ogawa, Som D. Mukherjee, Marinos Tsiatas, Cristina Suárez, Sophie Wildsmith, Ugo De Giorgi and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO